For patients taking NAMENDA®


(memantine HCl) for moderate to severe Alzheimer’s disease TRANSITION TO NAMENDA XR®


NAMENDA TWICE A DAY TODAY


NAMENDA XR ONCE A DAY TOMORROW


If your loved one is currently taking twice-a-day NAMENDA tablets, ask the doctor about transitioning to


once-a-day NAMENDA XR Q NAMENDA XR is an extended-release formulation of NAMENDA that offers convenient, once-a-day dosing and can be taken with or without food at any time of the day


Q NAMENDA XR capsules can be opened and the contents sprinkled on applesauce. Except when sprinkled on applesauce, the capsules should be swallowed whole. They should not be divided, chewed, or crushed


Q Most patients already taking NAMENDA tablets twice a day can start taking NAMENDA XR capsules once a day, the very next day NAMENDA XR®


NAMENDA XR is available by prescription only. There is no evidence that NAMENDA XR prevents or slows the underlying disease process in patients with Alzheimer’s disease.


Important Risk Information Who should NOT take NAMENDA XR?


NAMENDA XR should not be taken by anyone who is allergic (hypersensitive) to memantine, the active substance in NAMENDA XR, or who has had a bad reaction to NAMENDA XR or any of its ingredients. What should be discussed with the healthcare provider before taking NAMENDA XR?


Before starting NAMENDA XR, talk to the healthcare provider about all of the patient’s past and present medical conditions, including: Q Seizure disorders Q Difficulty passing urine Q Liver or kidney problems


If the patient is taking other medications (including those without a prescription), ask the healthcare provider if NAMENDA XR is right for the patient. Q Certain medications, changes in diet, or medical conditions may affect the amount of NAMENDA XR in the body and possibly increase side effects.


What are the possible side effects of NAMENDA XR?


The most common side effects associated with NAMENDA XR treatment are headache, diarrhea, and dizziness. This is not a complete list of side effects.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.


Please see brief summary of full Prescribing Information for NAMENDA XR on adjacent page.


(memantine hydrochloride) extended-release capsules are approved for the treatment of moderate to severe Alzheimer’s disease.


NAMENDA®


and NAMENDA XR®


are registered trademarks of Merz Pharma GmbH & Co. KGaA.


©2014 Forest Laboratories, LLC.


NXR18259


10/14 © PARADE Publications 2014. All rights reserved


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20